Apnimed Closes Upsized $220.8 Million IPO to Advance Oral Therapy for Obstructive Sleep Apnea
核心洞察
Apnimed closed its upsized initial public offering, raising $220.8 million in gross proceeds including full exercise of the underwriters' overallotment option.
The company's common stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD."
Apnimed's lead candidate AD109 has completed two Phase 3 trials for mild, moderate, and severe OSA, with an NDA assigned a PDUFA goal date of February 28, 2027.
Apnimed, Inc. (搜索), a Cambridge, Massachusetts-based late-stage clinical pharmaceutical company, has closed its upsized initial public offering, raising aggregate gross proceeds of $220.8 million before deducting underwriting discounts, commissions, and offering expenses. The offering included the full exercise by underwriters of their overallotment option to purchase an additional 1,800,000 shares, bringing the total shares sold to 13,800,000 at a price of $16.00 per share.
The company's common stock began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol "APMD." BofA Securities (搜索), Evercore ISI (搜索), Cantor, and LifeSci Capital (搜索) acted as joint book-running managers for the offering. The registration statements relating to the offering were filed with the Securities and Exchange Commission and became effective on July 30, 2026.
A Novel Oral Approach to Obstructive Sleep Apnea (搜索)
Apnimed is focused on discovering, developing, and commercializing novel oral therapies that address the neurobiology of sleep-related breathing diseases. The company's lead product candidate, AD109, is designed to improve oxygenation in individuals living with obstructive sleep apnea (搜索) (OSA). According to the company, the current treatment landscape for OSA has been "historically limited to cumbersome devices or invasive surgeries."
Apnimed believes that the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. The company also contends that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of the disease's pathophysiology.
Regulatory Progress and Upcoming Milestones
AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate, and severe OSA. Apnimed's New Drug Application for AD109 has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027. If approved, AD109 could become what the company describes as "the catalyst for a new oral treatment paradigm" for obstructive sleep apnea (搜索).
The company envisions a new era in which novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people obtain the oxygen and restorative sleep needed to thrive.